Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myeloma stem cell phenotype. Implications for treatment

J Epstein1

  • 1Division of Hematology/Oncology, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, USA.

Hematology/Oncology Clinics of North America
|February 1, 1997
PubMed
Summary

Myeloma cell heterogeneity reflects differentiation, impacting treatment response. Targeting both immature and mature myeloma cells may improve outcomes, but the role of early clonal B cells requires further clarification for curative strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evolution of a Client-Level Dataset: 20 Years of National Child Traumatic Stress Network Data Collection.

International journal of methods in psychiatric research·2026
Same author

Assessing domain match and feasibility of candidate instruments matching with OMERACT endorsed domains to measure flare in knee and hip osteoarthritis.

Seminars in arthritis and rheumatism·2024
Same author

An algorithm to determine the date when the McDonald criteria are met for the diagnosis of relapsing-remitting multiple sclerosis.

Revue neurologique·2022
Same author

Development and validation of the Flare-OA questionnaire for measuring flare in knee and hip osteoarthritis.

Osteoarthritis and cartilage·2022
Same author

Evaluation of the quality of the care pathway for patients with multiple sclerosis in France: Results of an original study of a cohort of 700 patients.

Revue neurologique·2021
Same author

Cystic papillary adenoma of the seminal vesicle.

BMC urology·2021

Area of Science:

  • Hematology
  • Oncology
  • Cancer Biology

Background:

  • Myeloma cell populations exhibit phenotypic heterogeneity, indicative of a differentiation process integral to the disease.
  • Immature and mature myeloma cells interact differently with their microenvironment, leading to varied responses to chemotherapy.
  • Current treatment strategies may not adequately address this heterogeneity, potentially limiting therapeutic efficacy.

Purpose of the Study:

  • To explore the implications of myeloma cell phenotypic heterogeneity on disease progression and treatment response.
  • To investigate the differential interactions of immature and mature myeloma cells with their microenvironment.
  • To highlight the need for treatment strategies that target all myeloma cell populations, including early clonal B cells.

Main Methods:

Related Experiment Videos

  • Analysis of myeloma cell phenotypic heterogeneity and its relation to differentiation.
  • Assessment of microenvironmental interactions of immature versus mature myeloma cells.
  • Evaluation of molecular genetic techniques, such as allele-specific oligonucleotide PCR (ASO-PCR), for clonal cell detection and monitoring.

Main Results:

  • Myeloma cell differentiation is a key aspect of phenotypic heterogeneity.
  • Immature and mature myeloma cells exhibit distinct microenvironmental interactions and chemotherapy responses.
  • Molecular genetic techniques offer sensitive detection of clonal cells, aiding in monitoring treatment efficacy.

Conclusions:

  • Tailoring treatments to target both immature and mature myeloma cells could significantly improve patient outcomes.
  • Clarifying the biologic significance of early clonal B cells is crucial for developing rational, curative treatment approaches.
  • Further research is needed to develop protocols for eliminating all clonal cells and purging stem cell harvests.